

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : A61K 31/48, 47/36, 47/40		A2	(11) International Publication Number: WO 94/22445 (43) International Publication Date: 13 October 1994 (13.10.94)
(21) International Application Number: PCT/EP94/00891 (22) International Filing Date: 18 March 1994 (18.03.94) (30) Priority Data: 9300297 26 March 1993 (26.03.93) BE 9300298 26 March 1993 (26.03.93) BE 9300299 26 March 1993 (26.03.93) BE (71)(72) Applicant and Inventor: MERKUS, Franciscus, W., H., M. [NL/BE]; Antwerpsesteenweg 165, B-2350 Vosselaar (BE). (74) Agent: LOUËT FEISSER, Arnold; Trenité Van Doorne, P.O. Box 75265, NL-1070 AG Amsterdam (NL).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  Published Without international search report and to be republished upon receipt of that report.	
(54) Title: PHARMACEUTICAL COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF DIHYDROERGOTAMINE, APO-MORPHINE AND MORPHINE			
(57) Abstract  The invention relates to pharmaceutical compositions for the intranasal administration of dihydroergotamine, apomorphine and morphine comprising one of these pharmacologically active ingredients in combination with a cyclodextrin and/or a disaccharide and/or a polysaccharide and/or a sugar alcohol.			

BEST AVAILABLE COPY

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PHARMACEUTICAL COMPOSITIONS FOR INTRANASAL ADMINISTRATION  
OF DIHYDROERGOTAMINE, APOMORPHINE AND MORPHINE

5 This invention is related to pharmaceutical compositions  
for nasal administration of dihydroergotamine, apomorphine  
and morphine, and methods of administering such  
compositions.

10 Dihydroergotamine mesylate (DHE) has been used in migraine  
therapy already for a long time. In patients with migraine  
attacks, DHE is suitable for basic interval treatment using  
tablets or solution, both for oral application, as well as  
for acute treatment by intravenous or intramuscular  
15 injection. DHE has been introduced in a nasal spray to  
avoid the parenteral and the oral route of administration.  
The nasal spray seems a good alternative, because it is  
less painful, less expensive and less inconvenient than  
injection therapy. Secondly, nausea and vomiting are common  
20 in migraine patients, making a nasal spray much more  
efficient than oral treatment.

A nasal spray containing DHE 4 mg/ml in an aqueous solution  
has been studied extensively by a number of investigators.  
25 Some of these investigators report, that besides DHE the  
nasal spray also contains glucose 5% and caffeine 1%. It  
was found that 1 mg of DHE, nasally administered, had the  
equivalence of 10 mg orally, and almost 40% of the  
bioavailability of the i.m. administration (PG Andersson  
30 and LT Jespersen, Cephalalgia 1986; 6: 51-54).

The maximal vasoconstrictor effect of 1 mg nasal DHE  
amounted to about 40%, of 0.5 mg i.m. DHE to about 50% of  
the initial venous diameter (W.H. Aellig and J. Rosenthaler,  
35 Eur. J. Clin. Pharmacol. 1986; 30: 581-584).

Nasal DHE appeared to be equally effective than a  
combination of oral ergotamine and caffeine in relieving

migraine attacks (D. Wirt et al, Cephalalgia 1989; 9, suppl. 10: 410-411). Another study in 904 patients confirmed the efficacy of nasal DHE and reported side effects in 18.4% of patients: nasal irritation, nausea, vomiting, fatigue, vertigo, breathlessness, tachycardia and perspiration. Only 3.9% of the patients refused further treatment with nasal DHE (G. Jenzer and M.F. Bremgartner, Schweiz. Rundsch. Med. Prax. 1990; 79: 914-917). Lataste et al (Cephalalgia 1989; 9 suppl. 10: 342-343) and Di Serio et al (Cephalalgia 1989; 9 suppl. 10: 344-345), confirm the efficacy of nasal DHE in the acute management of migraine. In contrast, Tulunay et al (Cephalalgia 1987; 7: 131-133) found little difference in nasal DHE and placebo.

Most of these studies are very encouraging and therefore nasal DHE, in the pharmaceutical composition studied by the above mentioned authors, seems an interesting alternative for oral and parenteral DHE preparations. Nasal DHE in the composition of DHE mesylate 4 mg/ml in 5% glucose and 1% caffeine, is available on prescription in several countries (e.g. Switzerland, France, Belgium).

Nevertheless, there is an urgent need for another DHE nasal drug formulation, because the nasal preparation, presently on the market, is not stable. It is on the market as a separate glass ampoule (containing the DHE formulation) which has to be broken by the patient and sprayed in the nose using a separate spray device. After opening of the ampoule, the spray can be used no longer than 24 hours.

Accordingly, it is an object of the invention to provide a highly stable pharmaceutical composition, suitable for nasal administration, capable of introducing efficiently a therapeutical amount of DHE into the human body. It has surprisingly been found that a pharmaceutically acceptable DHE composition can be formulated, suitable for nasal administration, without the presence of a special

caffeine-glucose vehicle and without the necessity of presenting the formulation in a separate glass ampoule.

According to the invention, the nasal pharmaceutical composition contains DHE and/or a salt of DHE (mesylate or tartrate) and a cyclodextrin and/or other saccharides and/or sugar alcohols. Such compositions appear to result in a surprisingly high bioavailability and a superior stability of DHE.

10

The term "cyclodextrins" refers to cyclic oligosaccharides, like  $\alpha$ -,  $\beta$ - and  $\gamma$ -cyclodextrin and their derivatives, preferably  $\beta$ -cyclodextrin and its derivatives, preferably methylated  $\beta$ -cyclodextrin, with a degree of  $\text{CH}_3$ -substitution between 0.5 and 3.0, more preferably between 1.7 and 2.1.

15

The term "saccharides" refers to disaccharides, like lactose, maltose, saccharose and also refers to polysaccharides, like dextrans, with an average molecular weight between 10.000 and 100.000, preferably 40.000 and 70.000. The term "sugar alcohols" refers to mannitol and sorbitol.

20

The nasal composition, according to the invention, can be administered as a nasal spray, nasal drop, suspension, gel, ointment, cream or powder. The administration of the nasal composition may also take place using a nasal tampon or nasal sponge, containing the invention composition.

25

In particular, powder formulations show a surprisingly high bioavailability and superior stability of the DHE. In addition, powder formulations have the advantage that no preservatives are necessary. Preservatives are known to decrease the ciliary movement, which may be harmful in chronic nasal medication (Hermens W.A.J.J. and Merkus F.W.H.M., Pharm. Res. 1987; 4: 445-449).

30

35

Nasal powder compositions can be made by mixing the active agent and the excipient, both possessing the desired particle size. Other methods to make a suitable powder formulation can be selected. Firstly, a solution of the active agent and the cyclodextrin and/or the other saccharide and/or sugar alcohol is made, followed by precipitation, filtration and pulverization. It is also possible to remove the solvent by freeze drying, followed by pulverization of the powder in the desired particle size by using conventional techniques, known from the pharmaceutical literature. The final step is size classification for instance by sieving, to get particles that are less than 100 microns in diameter, preferably between 50 and 100 microns in diameter. Powders can be administered using a nasal insufflator. Powders may also be administered in such a manner that they are placed in a capsule. The capsule is set in an inhalation or insufflation device. A needle is penetrated through the capsule to make pores at the top and the bottom of the capsule and air is sent to blow out the powder particles. Powder formulation can also be administered in a jet-spray of an inert gas or suspended in liquid organic fluids.

Also the active agent can be brought into a viscous basis, using vehicles, conventionally used, for example natural gums, methylcellulose and derivatives, acrylic polymers (carbopol) and vinyl polymers (polyvinylpyrrolidone). In the invention compositions many other excipients, known from the pharmaceutical literature, can be added, such as preservatives, surfactants, co-solvents, adhesives, anti-oxidants, buffers, viscosity enhancing agents, and agents to adjust the pH or the osmolarity.

The required amount for a nasal administration of a liquid or semi-solid nasal administration form is generally between 0.05 ml and 0.2 ml, preferably about 0.1 ml per nostril. The amount of a powder nasal formulation is

generally between 1 and 15 mg, preferably about 5 to 10 mg per nostril. Doses of DHE in the nasal pharmaceutical composition of the invention, suitable in the treatment of migraine attacks, are preferably in the range from 0.25 to 0.5 mg per nostril.

The following examples illustrate the invention in more detail, but are not construed as limiting the invention:

10

EXAMPLE 1 (liquid)

Dihydroergotamine mesylate	250 mg
Methyl- $\beta$ -cyclodextrin D.S. 1.8	2.5 g
Benzalkonium Chloride	0.01 %
15 Sodium EDTA	0.05-0.1 %
Sorbitol	5 %
Purified water to	100 ml
100 $\mu$ l = 250 $\mu$ g DHE mesylate	

20 EXAMPLE 2 (gel)

Dihydroergotamine mesylate	0.5 g
Methyl- $\beta$ -cyclodextrin D.S. 1.8	5 g
Benzalkonium Chloride	0.01 %
Sodium EDTA	0.05-0.1 %
25 Sorbitol	5 %
Hydroxypropylmethylcellulose	1-2 %
Purified water to	100 ml
100 $\mu$ l gel = 500 $\mu$ g DHE	

30 EXAMPLE 3A (powder)

Dihydroergotamine mesylate	0.5 mg
Methyl- $\beta$ -cyclodextrin	5 mg
Mannitol	4.5 mg
10 mg powder = 500 $\mu$ g DHE mesylate	

35

EXAMPLE 3B (powder)

Dihydroergotamine mesylate	0.5 mg
Dextran (average M.W. 70.000)	9.5 mg
10 mg powder = 500 µg DHE mesylate	

5

EXAMPLE 3C (powder)

Dihydroergotamine mesylate	0.5 mg
β-cyclodextrin	5 mg
Lactose	4.5 mg

10 10 mg powder = 500µg DHE mesylate

Apomorphine is a very potent dopamine agonist. It is used as an adjunctive medication in the treatment of Parkinson disease, complicated by motor fluctuations. Recently, encouraging results have been reported on the intranasal application of apomorphine in patients with Parkinson disease to relieve "off-period" symptoms in patients with response fluctuations (T. van Laar et al, Arch. Neurol. 1992; 49: 482-484). The intranasal applied apomorphine, used by these authors, consisted of an aqueous solution of apomorphine HCl 10 mg/ml. This formulation is also used for parenteral application and is published in different Pharmacopoeia's.

The exact nasal composition formulation used in the study by T. van Laar et al (1992) was:

Apomorphine HCl 0.5 H <sub>2</sub> O	1 g
Sodium metabisulphite	0.100 g
Sodium EDTA	0.010 g
NaCl	0.600 g
Benzalkonium Chloride	0.01 %
NaH <sub>2</sub> PO <sub>4</sub> ·2H <sub>2</sub> O	0.150 g
Na <sub>2</sub> HPO <sub>4</sub> ·2H <sub>2</sub> O	0.050 g

NaOH 1 M to adjust pH at 5.8  
purified water to 100 ml

(from Pharm. Weekblad 1991; 126: 1113-1114)

By a metered dose nebulizer a dose of 1 mg apomorphine HCl (0.1 ml of the solution) was delivered with each nasal application by puff to the patients. A great disadvantage of this aqueous solution is the instability of the apomorphine.

An object of the invention is a nasal formulation of apomorphine with an improved bioavailability and stability of apomorphine.

According to the invention, the nasal pharmaceutical composition contains apomorphine and/or apomorphine salts and a cyclodextrin and/or other saccharides and/or sugar alcohols. Such compositions appear to result in a surprisingly high bioavailability and superior stability of apomorphine.

The term "cyclodextrins" refers to cyclic oligosaccharides, like  $\alpha$ -,  $\beta$ - and  $\gamma$ -cyclodextrin and their derivatives, preferably  $\beta$ -cyclodextrin and its derivatives, preferably methylated  $\beta$ -cyclodextrin, with a degree of  $\text{CH}_3$ -substitution between 0.5 and 3.0, more preferably between 1.7 and 2.1. The term "saccharides" refers to disaccharides, like lactose, maltose, saccharose and also refers to polysaccharides, like dextrans, with an average molecular weight between 10.000 and 100.000, preferably 40.000 and 70.000. The term "sugar alcohols" refers to mannitol and sorbitol.

The nasal composition, according to the invention, can be administered as a nasal spray, nasal drop, suspension, gel, ointment, cream or powder. The administration of the nasal composition may also take place using a nasal tampon or nasal sponge, containing the invention composition.

In particular, powder formulations show a surprisingly high bioavailability and superior stability of the apomorphine.

In addition, powder formulations have the advantage that no preservatives are necessary. Preservatives are known to decrease the ciliary movement, which may be harmful in chronic nasal medication (Hermens W.A.J.J. and Merkus F.W.H.M., Pharm. Res. 1987; 4: 445-449).

Nasal powder compositions can be made by mixing the active agent and the excipient, both possessing the desired particle size. Other methods to make a suitable powder formulation can be selected. Firstly, a solution of the active agent and the cyclodextrin and/or the other saccharide and/or sugar alcohol is made, followed by precipitation, filtration and pulverization. It is also possible to remove the solvent by freeze drying, followed by pulverization of the powder in the desired particle size by using conventional techniques, known from the pharmaceutical literature. The final step is size classification for instance by sieving, to get particles that are less than 100 microns in diameter, preferably between 50 and 100 microns in diameter. Powders can be administered using a nasal insufflator. Powders may also be administered in such a manner that they are placed in a capsule. The capsule is set in an inhalation or insufflation device. A needle is penetrated through the capsule to make pores at the top and the bottom of the capsule and air is sent to blow out the powder particles. Powder formulation can also be administered in a jet-spray of an inert gas or suspended in liquid organic fluids.

Also the active agent can be brought into a viscous basis, using vehicles, conventionally used, for example natural gums, methylcellulose and derivatives, acrylic polymers (carbopol) and vinyl polymers (polyvinylpyrrolidone). In the invention compositions many other excipients, known from the pharmaceutical literature, can be added, such as preservatives, surfactants, co-solvents, adhesives,

anti-oxidants, buffers, viscosity enhancing agents, and agents to adjust the pH or the osmolarity.

The required amount for a nasal administration of a liquid or semi-solid nasal administration form is generally between 0.05 ml and 0.2 ml, preferably about 0.1 ml per nostril. The amount of a powder nasal formulation is generally between 1 and 15 mg, preferably about 5 to 10 mg per nostril. Doses of apomorphine in the pharmaceutical composition of the present invention, suitable in the treatment of Parkinson disease, are generally in the range of 0.1 to 2mg, preferably between 0.5 mg and 1 mg per nostril.

The following examples illustrate the present invention in more detail, but are not construed as limiting the invention:

EXAMPLE 1A (powder)

Apomorphine base	1 mg
Methyl- $\beta$ -cyclodextrin D.S. 2.1	5 mg
Mannitol	4 mg
10 mg powder = 1 mg Apomorphine	

EXAMPLE 1B (powder)

Apomorphine HCl	2 mg
Mannitol	18 mg
20 mg powder = 2 mg Apomorphine HCl	

EXAMPLE 1C (powder)

Apomorphine HCl	1 mg
Dextran (average M.W. 70.000)	9 mg
10 mg powder = 1 mg Apomorphine HCl	

EXAMPLE 2 (gel)

	Apomorphine HCl	500 mg
	Methylated- $\beta$ -cyclodextrin D.S. 1.8	2.5 g
	Hydroxypropylmethylcellulose	1-2 g
5	Benzalkonium Chloride	0.01 %
	Sodium EDTA	0.1 %
	Sodium metabisulphite	0.15 %
	Sorbitol	4 %
	pH adjusted to	4.5 - 5.5
10	purified water to	100 ml
	0.2 ml gel = 1 mg Apomorphine HCl	

EXAMPLE 3 (liquid)

	Apomorphine HCl	1 g
15	Methylated- $\beta$ -cyclodextrin D.S. 1.1	4 g
	Sodium metabisulphite	0.15 %
	Sodium EDTA	0.1 %
	Benzalkonium Chloride	0.01 %
	NaCl	0.8 %
20	pH adjusted to	4.5 - 5.5
	purified water to	100 ml
	100 $\mu$ l = 1 mg Apomorphine HCl	

Morphine is one of the strongest analgesics. Morphine  
25 therapy is restricted to two groups of patients. Firstly,  
to hospitalized patients, after surgery and secondly, to  
cancer and burn patients. The latter treatment is chronic.  
Morphine is administered generally by injection and in  
chronic treatment by sustained release oral preparations.  
30 After single oral administration morphine has a poor  
effect, mainly due to a large first pass effect. Secondly,  
the oral route is not possible when the patient shows  
severe nausea, vomiting, bowel obstruction or confusion.  
There is a need for a non-parenteral administration, other  
35 then oral, because injection therapy needs interference of  
(para)medical personnel and is painful.

Buccal administration of morphine have been proposed (MDD Bell et al, Lancet 1985; 1: 71-73), but this route did not find a large acceptance in practice. Recently rectal administration of morphine has been studied (T.J. Wilkinson et al, Cancer Chemother. Pharmacol 1992; 31: 251-254 and N Babul et al Clin. Pharmacol. Ther. 1993; 54: 286-292). From both publications it can be concluded that rectal application in some cases may be an alternative when the parenteral route is impractical or undesirable and the oral route is not available due to the patients condition. Nasal administration of a strong analgesic could be a good alternative to parenteral therapy, because it may give a very rapid absorption and no first pass effect.

To overcome the drawbacks of the oral and parenteral routes of administration of morphine, the use of a nasal spray has been proposed (S.L. Verweij and R. van Gijn: Can morphine be administered nasally? Ziekenhuisfarmacie (Dutch) 1988; 4: 73-77). The composition of the nasal spray in this study was:

Morphine HCl.3H <sub>2</sub> O	1.50 g
Sodium metabisulphite	0.03 g
Sodium EDTA	0.003 g
25 Benzylalcohol	0.3 ml
Propylene glycol	6 ml
Phosphate Buffer (0.01 mol/L; pH 6.00)	30 ml
Per puff of 100 µl the dose of morphine is	5 mg.

In 7 volunteers Verweij and van Gijn studied the pharmacokinetics of morphine after 4 puffs of about 100 µl ( 2 times 1 puff of 100, µl in each nostril). The exact dose which was delivered to the volunteers was 16 mg of morphine (range 15-18 mg) and the bioavailability of morphine from this nasal spray was 26-35%. The bioavailability of morphine after oral application is estimated to be about 40% (J. Säwe, Clin. Pharmacokinetics

1986; 11: 87-106 ). This means, that the bioavailability of morphine after giving the nasal spray as described by Verweij and van Gijn is relatively low. After nasal absorption there is no first pass effect and therefore the  
5 nasal bioavailability should be higher than the oral.

The nasal absorption of morphine has been studied also by F Chast et al (J. Pharm. Clin. 1992; 11: 257-261 ). They delivered nasally and orally 20 mg morphine acetate in an  
10 aqueous solution to 6 patients and compared the nasal absorption with the oral absorption of the same solution. They found, as expected, higher blood levels of morphine after the nasal application. Unfortunately, the nasal  
15 solutions, as described by the preceding studies of Verweij and van Gijn and of Chast and coworkers, are not stable and the bioavailability of morphine can be improved.

An object of the invention is to provide a highly stable pharmaceutical composition, suitable for nasal  
20 administration, and showing an superior bioavailability of morphine.

According to the invention, the nasal pharmaceutical composition contains morphine and/or morphine salts  
25 (hydrochloride, sulphate, acetate) and a cyclodextrin and/or other saccharides and/or sugar alcohols. Such compositions appear to result in a surprisingly high bioavailability and superior stability of morphine.

30 The term "cyclodextrins" refers to cyclic oligosaccharides, like  $\alpha$ -,  $\beta$ - and  $\gamma$ -cyclodextrin and their derivatives, preferably  $\beta$ -cyclodextrin and its derivatives, preferably methylated  $\beta$ -cyclodextrin, with a degree of  $\text{CH}_3$ -substitution between 0.5 and 3.0, more preferably between 1.7 and 2.1.

35 The term "saccharides" refers to disaccharides, like lactose, maltose, saccharose and also refers to polysaccharides, like dextrans, with an average molecular

weight between 10.000 and 100.000, preferably 40.000 and 70.000. The term "sugar alcohols" refers to mannitol and sorbitol.

- 5 The nasal composition, according to the invention, can be administered as a nasal spray, nasal drop, suspension, gel, ointment, cream or powder. The administration of the nasal composition may also take place using a nasal tampon or nasal sponge, containing the invention composition.

10

In particular, powder formulations show a surprisingly high bioavailability and superior stability of the morphine. In addition, powder formulations have the advantage that no preservatives are necessary. Preservatives are known to  
15 decrease the ciliary movement, which may be harmful in chronic nasal medication (Hermens W.A.J.J. and Merkus F.W.H.M., Pharm. Res. 1987; 4: 445-449).

Nasal powder compositions can be made by mixing the active  
20 agent and the excipient, both possessing the desired particle size. Other methods to make a suitable powder formulation can be selected. Firstly, a solution of the active agent and the cyclodextrin and/or the other saccharide and/or sugar alcohol is made, followed by  
25 precipitation, filtration and pulverization. It is also possible to remove the solvent by freeze drying, followed by pulverization of the powder in the desired particle size by using conventional techniques, known from the pharmaceutical literature. The final step is size  
30 classification for instance by sieving, to get particles that are less than 100 microns in diameter, preferably between 50 and 100 microns in diameter. Powders can be administered using a nasal insufflator. Powders may also be administered in such a manner that they are placed in a  
35 capsule. The capsule is set in an inhalation or insufflation device. A needle is penetrated through the capsule to make pores at the top and the bottom of the

capsule and air is sent to blow out the powder particles. Powder formulation can also be administered in a jet-spray of an inert gas or suspended in liquid organic fluids.

- 5 Also the active agent can be brought into a viscous basis, using vehicles, conventionally used, for example natural gums, methylcellulose and derivatives, acrylic polymers (carbopol) and vinyl polymers (polyvinylpyrrolidone). In the invention compositions many other excipients, known  
10 from the pharmaceutical literature, can be added, such as preservatives, surfactants, co-solvents, adhesives, anti-oxidants, buffers, viscosity enhancing agents, and agents to adjust the pH or the osmolarity.
- 15 The required amount for a nasal administration of a liquid or semi-solid nasal administration form is generally between 0.05 ml and 0.2 ml, preferably about 0.1 ml per nostril. The amount of a powder nasal formulation is generally between 1 and 15 mg, preferably about 5 to 10 mg  
20 per nostril.

Doses of morphine in the pharmaceutical composition of the present invention, suitable in the treatment of pain, are in the range from 1 to 20 mg.

25

The following examples illustrate the present invention in more detail, but are not construed as limiting the invention:

30 EXAMPLE 1A (powder)

Morphine sulphate 5H <sub>2</sub> O	13.3 mg
Methyl- $\beta$ -cyclodextrin D.S. 2.1	11.7 mg
Mannitol	5 mg
30 mg powder = 10 mg morphine	

35

EXAMPLE 1B (powder)

Morphine sulphate 5H <sub>2</sub> O	13.3 mg
β-cyclodextrin	6.7 mg
20 mg powder = 10 mg morphine	

5

EXAMPLE 1C (powder)

Morphine HCl 3H <sub>2</sub> O	13.1 mg
Dextran (average MW 70.000)	16.9 mg
30 mg powder = 10 mg morphine	

10

EXAMPLE 2(gel)

Morphine (as salt)	1.5 g
Methyl-β-cyclodextrin D.S. 1.8	5 g
(Hydroxypropyl)methylcellulose	1-2 %
15 Benzalkonium Chloride	0.01 %
Sodium EDTA	0.1 %
Sodium metabisulphite	0.15 %
Sorbitol	4 %
Purified water to	50 ml
20 0.2 ml gel = 6 mg morphine	

EXAMPLE 3 (liquid)

Morphine (as salt)	4 g
Methyl-β-cyclodextrin D.S. 2.1	4 g
25 Methylcellulose	0.25 %
Sodium metabisulphite	0.15 %
Sodium EDTA	0.1 %
Benzalkonium Chloride	0.01 %
Mannitol	4 %
30 Purified water to	100 ml
100 μl = 4 mg morphine	

## CLAIMS

1. A pharmaceutical composition for nasal administration comprising dihydroergotamine and/or a  
5 dihydroergotamine-salt and a cyclodextrin and/or an other saccharide and/or a sugar alcohol.
2. A pharmaceutical composition according to claim 1, wherein the dihydroergotamine salt is dihydroergotamine  
10 mesylate and/or tartrate.
3. A pharmaceutical composition according to claim 1 or 2, wherein the cyclodextrin is  $\alpha$ - or  $\beta$ - or  $\gamma$ -cyclodextrin and/or a derivative of  $\alpha$ - or  $\beta$ - or  $\gamma$ -cyclodextrin.  
15
4. A pharmaceutical composition according to any of claims 1 - 3, wherein the cyclodextrin is  $\beta$ -cyclodextrin and/or a derivative.
- 20 5. A pharmaceutical composition according to claim 4, wherein the derivative of  $\beta$ -cyclodextrin is a methylated  $\beta$ -cyclodextrin with a degree of substitution between 0.5 and 3.0.
- 25 6. A pharmaceutical composition according to any of claims 1 - 5, wherein the saccharides a disaccharide, preferably lactose and/or a polysaccharide, preferably dextran, having an average molecular weight between 10.000 and 100.000, preferably between 40.000 and  
30 70.000 .
7. A pharmaceutical composition according to any of claims 1-6, wherein the sugar alcohol is mannitol and/or sorbitol.  
35

8. A pharmaceutical composition according to any of claims 1-7 in powder form, suitable for nasal administration, wherein the particles of the powder have a diameter between 50-100 microns.
- 5 9. A process of preparing a nasal pharmaceutical composition according to any of claims 1 - 8, which process comprises combining dihydroergotamine and/or its salts with a cyclodextrin and/or a disaccharide and/or a polysaccharide and/or a sugar alcohol.
- 10 10. A method of treating migraine attacks by administering a pharmaceutical composition, according to any of claims 1 - 8, to the nasal mucosa.
- 15 11. A pharmaceutical composition for nasal administration comprising apomorphine and/or an apomorphine salt and a cyclodextrin and/or an other saccharide and/or a sugar alcohol.
- 20 12. A pharmaceutical composition according to claim 11, wherein the apomorphine salt is apomorphine hydrochloride.
- 25 13. A pharmaceutical composition according to claim 11 or 12, wherein the cyclodextrin is  $\alpha$ - or  $\beta$ - or  $\gamma$ -cyclodextrin and/or a derivative of  $\alpha$ - or  $\beta$ - or  $\gamma$ -cyclodextrin.
- 30 14. A pharmaceutical composition according to any of claims 11 - 13, wherein the cyclodextrin is  $\beta$ -cyclodextrin and/or a derivative.

15. A pharmaceutical composition according to claim 14,  
wherein the derivative of  $\beta$ -cyclodextrin is a  
methyalted  $\beta$ -cyclodextrin with a degree of substitution  
between 0.5 and 3.0.
16. A pharmaceutical composition according to any of claims  
11 - 15, wherein the saccharide is a disaccharide,  
preferably lactose and/or a polysaccharide, preferably  
dextran, having an average molecular weight between  
10.000 and 100.000, preferably between 40.000 and  
70.000.
17. A pharmaceutical composition according to any of claims  
11 - 16, wherein the sugar alcohol is mannitol and/or  
sorbitol.
18. A pharmaceutical composition according to any of claims  
11 - 17 in powder form, suitable for nasal  
administration, wherein the particles of the powder  
have a diameter between 50-100 microns.
19. A process of preparing a nasal pharmaceutical  
composition according to any of claims 11 - 18, which  
process comprises combining apomorphine and/or its  
salts with a cyclodextrin and/or a disaccharide and/or  
a polysaccharide and/or a sugar alcohol.
20. A method of treating Parkinson disease by administering  
a pharmaceutical composition according to any of claims  
11 - 18, to the nasal mucosa.

21. A pharmaceutical composition for nasal administration comprising morphine and/or morphine salts and a cyclodextrin and/or an other saccharide and/or a sugar alcohol.
22. A pharmaceutical composition according to claim 21, wherein the morphine salt is morphine hydrochloride and/or acetate and/or sulphate.
23. A pharmaceutical composition according to claim 21 or 22, wherein the cyclodextrin is  $\alpha$ - or  $\beta$ - or  $\gamma$ -cyclodextrin and/or a derivative of  $\alpha$ - or  $\beta$ - or  $\gamma$ -cyclodextrin.
24. A pharmaceutical composition according to any of claims 21 - 23, wherein the cyclodextrin is  $\beta$ -cyclodextrin and/or a derivative.
25. A pharmaceutical composition according to claim 24, wherein the derivative of  $\beta$ -cyclodextrin is a methylated  $\beta$ -cyclodextrin with a degree of substitution between 0.5 and 3.0.
26. A pharmaceutical composition according to any of claims 21 - 25, wherein the saccharide is a disaccharide, preferably lactose and/or a polysaccharide, preferably dextran, having an average molecular weight between 10.000 and 100.000, preferably between 40.000 and 70.000.
27. A pharmaceutical composition according to any of claims 21 - 26, wherein the sugar alcohol is mannitol and/or sorbitol.

28. A pharmaceutical composition according to any of claims  
21 - 27 in powder form, suitable for nasal  
administration, wherein the particles of the powder  
5 have a diameter between 50-100 microns.
29. A process of preparing a nasal pharmaceutical  
composition, according to any of claims 21 - 28, which  
• process comprises combining morphine and/or its salts  
10 with a cyclodextrin and/or a disaccharide and/or a  
polysaccharide and/or a sugar alcohol.
30. A method of relieving pain by administering a  
pharmaceutical composition according to any of claims  
15 21 - 28, to the nasal mucosa.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : <b>A61K 31/48, 47/36, 47/40, 31/485</b>		<b>A3</b>	(11) International Publication Number: <b>WO 94/22445</b>
			(43) International Publication Date: 13 October 1994 (13.10.94)
(21) International Application Number: <b>PCT/EP94/00891</b>		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 18 March 1994 (18.03.94)			
(30) Priority Data:			
9300297 26 March 1993 (26.03.93) BE			
9300298 26 March 1993 (26.03.93) BE			
9300299 26 March 1993 (26.03.93) BE			
(71)(72) Applicant and Inventor: MERKUS, Franciscus, W., H., M. [NL/BE]; Antwerpsesteenweg 165, B-2350 Vosselaar (BE).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(74) Agent: LOUËT FEISSER, Arnold; Trenité Van Doorne, P.O. Box 75265, NL-1070 AG Amsterdam (NL).		(88) Date of publication of the international search report: 5 January 1995 (05.01.95)	
(54) Title: PHARMACEUTICAL COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF DIHYDROERGOTAMINE, APO-MORPHINE AND MORPHINE			
(57) Abstract			
The invention relates to pharmaceutical compositions for the intranasal administration of dihydroergotamine, apomorphine and morphine comprising one of these pharmacologically active ingredients in combination with a cyclodextrin and/or a disaccharide and/or a polysaccharide and/or a sugar alcohol.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CC	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 94/00891

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 A61K31/48 A61K47/36 A61K47/40 A61K31/485

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB,A,1 592 563 (SANDOZ LTD) 8 July 1981 see claims 1,11,21; example 5 ---	1,2,6,9, 10
X	EP,A,0 463 653 (FARMITALIA CARLO ERBA S.R.L) 2 January 1992 see column 3, line 9 - line 15; claims 1,2 see column 7, paragraph 1 - paragraph 2 see column 8, line 32 - line 39 see the whole document	1-5,8-10
Y	---	11-15, 18-20, 23-25, 28-30
P,X	DE,A,42 07 922 (PHARMATECH GMBH) 23 September 1993 see examples 5, and, 6; table I see page 3, line 12 ---	1-10, 21-30
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

19 October 1994

Date of mailing of the international search report

24. 11. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Uiber, P

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 94/00891

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 094 157 (TAKEDA CHEMICALS IND. , LTD) 16 November 1983 see page 10, line 27 - page 11, line 4; claim 4 see page 7, line 8 - page 8, line 16 ---	1-30
Y	WO,A,91 09599 (PHARMACIA AB) 11 July 1991 see page 4, line 23 - line 34; claims 4,6; example 1 see page 3, line 14 - line 19 ---	1-30
Y	DEUTSCHE APOTHEKER ZEITUNG vol. 130, no. 44 , 1 November 1990 pages 2411 - 15 HERMENS ET AL 'Der Einfluss von Arzneimitteln auf die Bewegung nasaler Flimmerhaare' see page 2414, column 3, paragraph 1 - page 2415, paragraph 1 ---	1-30
X	US,A,5 169 849 (KIECHEL ET AL) 8 December 1992 see the whole document ---	1,2,8-10
Y	EP,A,0 475 482 (AKZO N.V.) 18 March 1992  see page 3, line 25; claim 1 ---	11,12, 16,18,19
P,Y	WO,A,93 15737 (DANBIOSYST UK LTD.) 19 August 1993 see the whole document ---	21-30
X	EP,A,0 205 282 (EUROCELTIQUE SA) 17 December 1986  see the whole document see the whole document -----	21,22, 26,27, 29,30  11,12, 16,19

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 94/00891

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims: 1-10
2. Claims: 11-20
3. Claims: 21-30

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 94/00891

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A-1592563	08-07-81	AT-B- 368881	25-11-82
		AU-B- 520754	25-02-82
		AU-A- 3078377	24-05-79
		CA-A- 1103585	23-06-81
		DE-A- 2750090	01-06-78
		DE-A- 2802113	26-07-79
		FR-A, B 2371454	16-06-78
		JP-C- 1467172	30-11-88
		JP-A- 53066440	13-06-78
		JP-B- 63013965	29-03-88
		NL-A- 7712552	23-05-78
		SE-B- 451944	09-11-87
		SE-A- 7712693	20-05-78
		US-A- 4462983	31-07-84
		US-A- 4758423	19-07-88
		BE-A- 860938	17-05-78
EP-A-0463653	02-01-92	JP-A- 4235927	25-08-92
DE-A-4207922	23-09-93	NONE	
EP-A-0094157	16-11-83	JP-B- 5024129	06-04-93
		JP-A- 59148717	25-08-84
		JP-C- 1593382	14-12-90
		JP-B- 2019092	27-04-90
		JP-A- 58189118	04-11-83
		JP-B- 5024130	06-04-93
		JP-A- 59021613	03-02-84
		CA-A- 1218606	03-03-87
		US-A- 4659696	21-04-87
		US-A- 4670419	02-06-87
WO-A-9109599	11-07-91	AU-A- 6977491	24-07-91
		EP-A- 0506774	07-10-92
		JP-T- 5504949	29-07-93
US-A-5169849	08-12-92	AT-B- 385656	10-05-88
		AU-B- 565613	24-09-87
		AU-A- 1085083	11-08-83
		BE-A- 895750	01-08-83

## INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 94/00891

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5169849		CA-A- 1197783	10-12-85
		CH-A- 653555	15-01-86
		DE-A, C 3302949	11-08-83
		FR-A, B 2539994	03-08-84
		GB-A, B 2114001	17-08-83
		JP-C- 1629242	20-12-91
		JP-B- 2053406	16-11-90
		JP-A- 58134017	10-08-83
		LU-A- 84613	08-09-83
		NL-A- 8300325	01-09-83
		SE-B- 454402	02-05-88
		SE-A- 8300495	02-08-83
EP-A-0475482	18-03-92	AU-B- 643920	25-11-93
		AU-A- 8341691	19-03-92
		CA-A- 2049811	14-03-92
		JP-A- 5078236	30-03-93
		US-A- 5292520	08-03-94
WO-A-9315737	19-08-93	AU-B- 3458093	03-09-93
EP-A-0205282	17-12-86	AU-B- 595801	12-04-90
		AU-A- 5828486	18-12-86
		CA-A- 1277913	18-12-90
		JP-A- 61286321	16-12-86
		US-A- 4940587	10-07-90

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**